Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
ZimVie will replace Tabula Rasa Healthcare in the S&P SmallCap 600 index on March 2, 2022. This change comes as Zimmer Biomet Holdings spins off ZimVie, effective March 1, 2022. Post spin-off, Zimmer Biomet will continue to be a part of the S&P 500 index. Tabula Rasa Healthcare is being removed due to its lack of representation in the small-cap market.
Zimmer Biomet Holdings has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2022. This dividend will be payable on April 29, 2022, to stockholders who are on record as of March 29, 2022. The company continues to position itself as a leader in medical technology, providing innovative products aimed at improving health and mobility. With a legacy spanning over 90 years, Zimmer Biomet strives to enhance the patient experience through its advanced digital and robotic technologies.
ZimVie, set to be a standalone publicly traded company from Zimmer Biomet (NYSE: ZBH), held its first Investor Day on February 7, 2022. The event highlighted its Spine and Dental offerings, market opportunities, and financial strategy. For 2022, ZimVie projects revenues of $1.0 billion, maintaining levels from 2021, with an adjusted EBITDA margin of 13.1% to 13.6%. Adjusted EPS is forecasted between $2.10 and $2.30. The ongoing COVID-19 pandemic presents risks to these projections as ZimVie aims to innovate within the $20 billion global dental and spine markets.
Zimmer Biomet Holdings has announced a dividend distribution of 80.3% of ZimVie Inc. shares to its shareholders on record as of February 15, 2022. Each shareholder will receive one share of ZimVie for every ten shares of Zimmer Biomet they own. The distribution will occur on March 1, 2022, with no fractional shares given; instead, fractional shares will be sold, and proceeds distributed as cash. ZimVie will begin 'when-issued' trading on NASDAQ on February 14, 2022, under the symbol 'ZIMVV'. Regular trading of ZimVie is set for the distribution date under 'ZIMV'.
Zimmer Biomet Holdings (NYSE: ZBH) reported its financial results for Q4 and the full year ended December 31, 2021. Q4 net sales fell to $2.038 billion, a 2.3% decrease year-over-year, while FY2021 sales rose 11.6% to $7.836 billion. The company faced a net loss of $84 million in Q4, although adjusted earnings were $409.2 million. Key challenges included impacts from China's volume-based procurement and ongoing pandemic pressures. The planned spin-off of its Dental and Spine units into a new entity, ZimVie, is set for March 1, 2022.
Zimmer Biomet Holdings (NYSE: ZBH) announced the filing of a Form 10 with the SEC for the spinoff of its Dental and Spine businesses into a new company named ZimVie. The Form 10 outlines ZimVie's business strategy and historical financials. ZimVie will hold a virtual Investor Day on February 7, 2022, featuring insights on its market opportunities and financial outlook. The spinoff aims to optimize resource allocation and is expected to close in Q1 2022. ZimVie will focus on dental and spine markets, headquartered in Westminster, Colorado.
Zimmer Biomet Holdings (NYSE: ZBH) will host a fourth quarter earnings conference call on February 7, 2022, at 8:30 a.m. ET. A detailed earnings report will be available at 6:30 a.m. ET on the same day. Investors can access the live audio webcast via Zimmer Biomet's Investor Relations website. For those wishing to join via telephone, calls can be made to (888) 312-9837 in the U.S., using conference ID 7278985. A recording will be available for replay until March 31, 2022.
ZBH announced that Chairman, President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 p.m. ET. The presentation will be accessible via a live webcast on Zimmer Biomet's Investor Relations website, with a replay available post-conference. Zimmer Biomet is recognized for its innovative medical technology solutions aimed at improving patient mobility and healthcare outcomes, supported by over 90 years of industry experience.
Zimmer Biomet Holdings (NYSE: ZBH) has priced its cash tender offers for certain outstanding senior notes, which include its 3.700% notes due 2023 and various other notes maturing from 2025 to 2045. As of November 29, 2021, approximately $211.48 million of the 2023 notes were tendered. The total amount for the maximum purchase price for eligible notes has been set at about $1.93 billion, following amendments. The tender offers will expire on December 13, 2021, and the early settlement is expected on December 1, 2021.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
